Detalhe da pesquisa
1.
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
N Engl J Med
; 390(4): 301-313, 2024 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38084760
2.
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 388(11): 1002-1014, 2023 Mar 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-36762851
3.
Teclistamab in Relapsed or Refractory Multiple Myeloma.
N Engl J Med
; 387(6): 495-505, 2022 08 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35661166
4.
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
N Engl J Med
; 384(8): 705-716, 2021 02 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-33626253
5.
Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma.
Haematologica
; 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38385280
6.
Plain Language Summary of the KarMMa-3 study of ide-cel or standard of care regimens in people with relapsed or refractory multiple myeloma.
Future Oncol
; 2024 Apr 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38651976
7.
Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network.
Lancet Oncol
; 24(6): e255-e269, 2023 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269857
8.
Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP-EBMT study.
Eur J Haematol
; 111(2): 181-190, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37082839
9.
Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(12): 811-818, 2023 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-37132225
10.
Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma.
N Engl J Med
; 381(8): 727-738, 2019 08 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-31433920
11.
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant in patients with newly diagnosed multiple myeloma (CASSIOPEIA): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(10): 1378-1390, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34529931
12.
Quality of life analyses in patients with multiple myeloma: results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study.
BMC Cancer
; 21(1): 993, 2021 Sep 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34488662
13.
Ultra-low depth sequencing of plasma cell DNA for the detection of copy number aberrations in multiple myeloma.
Genes Chromosomes Cancer
; 59(8): 465-471, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32259320
14.
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study.
Lancet
; 394(10192): 29-38, 2019 07 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31171419
15.
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.
Blood
; 131(3): 301-310, 2018 01 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-29150421
16.
A multicenter retrospective study of 223 patients with t(14;16) in multiple myeloma.
Am J Hematol
; 95(5): 503-509, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32072687
17.
Development and validation of a novel risk stratification algorithm for relapsed multiple myeloma.
Br J Haematol
; 187(4): 447-458, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31388996
18.
How I manage the toxicities of myeloma drugs.
Blood
; 129(17): 2359-2367, 2017 04 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-28275090
19.
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network.
Haematologica
; 104(12): 2358-2360, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31439675
20.
Proliferative glomerulonephritis with monoclonal immunoglobulin deposits in the native or posttransplant kidney.
Nephrol Dial Transplant
; 39(5): 888-892, 2024 Apr 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38192041